Access to targeted therapies in renal cell cancer

Jones, R. and DeSantis, M. (2013) Access to targeted therapies in renal cell cancer. Seminars in Oncology, 40(4), pp. 521-528. (doi: 10.1053/j.seminoncol.2013.05.012)

Full text not currently available from Enlighten.


There is limited access to targeted therapies for renal cancer in many parts of the western world. This is driven by reimbursement rather than regulatory issues. Indeed, only a small fraction of the global population benefits from unlimited reimbursement of targeted therapies. Dedicated bodies, such as the UK National Institute for Clinical Excellence, assess agents on their cost-effectiveness as well as their efficacy. The results have been disappointing for patients, with the majority of agents being rejected for reimbursement. Despite this trend, there is a general appetite to address cost and value in many part of the world. This article gives a current overview of this rapidly changing field.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Jones, R., and DeSantis, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Seminars in Oncology
ISSN (Online):1532-8708
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record